Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates

Core Viewpoint - Sarepta Therapeutics reported quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of$1.87 per share, representing an earnings surprise of -19.79% [1] - The company posted revenues of $658.41 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.83$396.78 million year-over-year [2] Financial Performance - Earnings per share (EPS) for the current quarter was $1.50, compared to$0.47 per share a year ago [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is $1.73, with expected revenues of$656.12 million, and for the current fiscal year, the EPS estimate is $10.94 on revenues of$3.03 billion [7] Market Performance - Sarepta Therapeutics shares have declined approximately 12% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's Zacks Rank is currently 2 (Buy), indicating expectations of outperforming the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry is currently in the top 24% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]